Ofatumumab
1 NDC across 1 manufacturer|0 Generic,1 Brand
Ofatumumab is used to treat lymphoid leukemia, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
In 2024, Medicare Part D spent $583 million on Ofatumumab across 60,000 claims for 7,188 beneficiaries.
Ofatumumab is available as 1 NDC from 1 manufacturer (0 generic, 1 brand), with NADAC prices from $24380.23 to $24380.23 per ML. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
1
0G / 1B
Manufacturers
1
competing in market
Price Spread
$24380.23 – $24380.23
per ML
7d Activity
avg -0.0% WoW · of 1 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing OFATUMUMAB
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
KESIMPTA 20 MG/0.4 ML PEN | $24380.2266 per ML | -0.03% |
Frequently Asked Questions
What is Ofatumumab used to treat?
Ofatumumab is used to treat lymphoid leukemia, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Ofatumumab?
In 2024, Medicare Part D spent $583 million on Ofatumumab across 60,000 claims for 7,188 beneficiaries.
How many Ofatumumab products are on the market?
The Ofatumumab drug market contains 1 NDC from 1 manufacturer — 0 generic and 1 brand product.
What is the price range for Ofatumumab?
NADAC reference prices for Ofatumumab range from $24380.2266 to $24380.2266 per ML.
Which manufacturers make Ofatumumab?
1 manufacturer lists Ofatumumab in NADAC. Ranked by number of NDCs, the largest are Novartis Pharmaceuticals Corporation (1).
How has the price of Ofatumumab changed recently?
Over the past 7 days, 0 Ofatumumab NDCs rose and 1 fell, with a market-wide average change of -0.0%.